18 related articles for article (PubMed ID: 14668544)
1. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
Itkin B; Garcia A; Straminsky S; Adelchanow ED; Pereyra M; Haab GA; Bardach A
PLoS One; 2021; 16(9):e0257976. PubMed ID: 34591928
[TBL] [Abstract][Full Text] [Related]
2. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell.
Liu K; Chen H; You Q; Shi H; Wang Z
Mol Cell Biochem; 2014 Jan; 386(1-2):117-24. PubMed ID: 24158524
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.
Munro EG; Jain M; Oliva E; Kamal N; Lele SM; Lynch MP; Guo L; Fu K; Sharma P; Remmenga S; Growdon WB; Davis JS; Rueda BR; Batra SK
Int J Gynecol Pathol; 2009 Mar; 28(2):127-33. PubMed ID: 19188823
[TBL] [Abstract][Full Text] [Related]
4. Could the truncated variant of ERBB2 be present in the squamous carcinomas of the cervix?
Costa C; Molina MA; Baró T; Aguilar A; De las Heras P; Fusté P; Mancebo G; Carreras R; Serrano S; Alameda F
Virchows Arch; 2008 Nov; 453(5):535-6. PubMed ID: 18818943
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
6. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
7. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
9. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
10. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.
Rosty C; Couturier J; Vincent-Salomon A; Genin P; Fréneaux P; Sigal-Zafrani B; Sastre-Garau X
Int J Gynecol Pathol; 2004 Jan; 23(1):13-7. PubMed ID: 14668544
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
